Zetia Cost in District of Columbia 2026: What You'll Actually Pay for Ezetimibe

What Does Zetia Cost in the District of Columbia in 2026?

Brand-name Zetia has a manufacturer list price near $380/month in DC, but the realistic cash price for generic ezetimibe 10 mg sits around $15/month at most DC retail and mail-order pharmacies. The gap between those two numbers is one of the widest in cardiovascular prescribing, and understanding it can save you hundreds of dollars annually.

The list price reflects what Merck charges wholesalers before any negotiated discounts, rebates, or patient assistance programs reduce it. Pharmacy benefit managers and insurance plans extract large rebates, so insured patients rarely see the sticker price. Uninsured or underinsured DC residents have three realistic options: generic ezetimibe at a GoodRx-type price, the Merck Savings Card, or compounded ezetimibe through a licensed District of Columbia 503A pharmacy.

Ezetimibe works by blocking the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestine, cutting dietary and biliary cholesterol absorption by roughly 50% [1]. The FDA approved ezetimibe in October 2002 under the brand name Zetia [2]. A generic became available in late 2017 after Merck's exclusivity period ended, and that generic is now the dominant dispensed form in DC.

The IMPROVE-IT trial (N=18,144) showed that adding ezetimibe 10 mg to simvastatin 40 mg lowered LDL-C by an additional 24% and reduced the composite of cardiovascular death, major coronary events, and stroke from 34.7% to 32.7% over a median 6-year follow-up, an absolute risk reduction of 2 percentage points [3]. That evidence base supports why clinicians prescribe it for tens of thousands of DC-area patients and why payers, including DC Medicaid, list it on formulary.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states that ezetimibe "can be used as first-line nonstatin therapy when statin therapy is contraindicated or not tolerated" and as add-on therapy in high-risk patients not meeting LDL-C goals on maximally tolerated statins [4]. That guideline language directly shapes DC Medicaid's prior authorization criteria.

DC Medicaid Coverage for Ezetimibe: What Prior Authorization Requires

DC Medicaid (administered through DC Department of Health Care Finance) covers ezetimibe on its Preferred Drug List with a prior authorization requirement. Approval is routinely granted when prescribers document a confirmed diagnosis of hyperlipidemia, a trial of at least one first-line statin (or a documented reason for statin intolerance), and an LDL-C level above the patient-specific goal [5].

The PA process in DC typically resolves within 72 hours for standard reviews and within 24 hours for expedited urgent requests. Most DC Medicaid managed care organizations, including AmeriHealth Caritas DC and MedStar Family Choice DC, follow the same core PA criteria as the fee-for-service program.

Patients enrolled in DC Medicaid pay $0 copay for ezetimibe once PA is approved, because DC Medicaid eliminated cost-sharing for most preferred formulary drugs under its low-income benefit structure. If a prescriber documents a failure of or contraindication to statins, PA approval rates run higher than 90% based on national Medicaid utilization data [6].

Medicaid coverage matters because roughly 38% of DC residents are enrolled in Medicaid or CHIP as of 2024, a share higher than any U.S. state [7]. Residents who earn between 138% and 200% of the federal poverty level and do not qualify for DC Medicaid may qualify for subsidized plans through DC Health Link, the District's ACA marketplace, where ezetimibe generics appear on Tier 2 formulary for most silver and gold plans.

Is Compounded Ezetimibe Legal in the District of Columbia?

Yes. Licensed 503A compounding pharmacies operating in the District of Columbia may legally compound ezetimibe for individual patients when a prescriber issues a patient-specific prescription [8]. A 503A pharmacy compounds in response to individual prescriptions rather than producing drug in bulk for general sale, which is the legal distinction from 503B outsourcing facilities under the Drug Quality and Security Act of 2013 [9].

Compounded ezetimibe is not FDA-approved as a finished product, and it is not bioequivalent-tested to the brand or generic. Prescribers who recommend compounded ezetimibe should document the clinical rationale, such as a documented allergy to an excipient in commercial tablets or a need for a dose not commercially available.

The practical price advantage is significant. Several DC-area compounding pharmacies and national 503A telehealth pharmacies ship to DC addresses price compounded ezetimibe at $0/month for patients enrolled in specific telehealth programs, compared to roughly $15/month for retail generic. That $0 price reflects bundled telehealth subscription models, not a government subsidy.

DC's Board of Pharmacy governs 503A pharmacies operating within the District and requires compliance with USP Chapter 795 standards for non-sterile compounding [10]. Patients should verify any compounding pharmacy's DC license through the DC Department of Health's online license verification portal before filling a prescription.

Which Insurance Plans Cover Zetia in the District of Columbia?

Nearly every major commercial insurer active in DC covers generic ezetimibe, though brand Zetia faces non-preferred or excluded status on most plans. Coverage tiers and copays vary by plan year.

Major Federal Employees Health Benefits (FEHB) plans, which cover a large share of DC's workforce given the concentration of federal employment, list generic ezetimibe on Tier 1 or Tier 2 formularies with copays ranging from $0 to $20/month. CareFirst BlueCross BlueShield, the dominant commercial insurer in DC, places generic ezetimibe on its Value Formulary Tier 2 with a roughly $15 copay for a 30-day supply [11].

Employer-sponsored plans offered through large DC employers, including federal agencies, universities, and hospital systems, typically cover generic ezetimibe without prior authorization. Brand Zetia, by contrast, may require step therapy documentation (proof the patient tried and failed the generic) before the plan covers the brand at a higher tier [12].

For DC residents buying individual or small-group coverage through DC Health Link, ezetimibe generics appear on Tier 2 for most silver QHPs at copays of $10 to $30/month after any deductible is met. Some plans apply the deductible to Tier 2 drugs, so a patient in a plan with a $1,500 deductible could pay the full negotiated rate until that deductible clears, typically $15 to $40/month for generic ezetimibe.

The 2025 Inflation Reduction Act drug price negotiation program does not yet include ezetimibe; it remains outside the initial 10 negotiated drugs under Medicare Part D [13]. Medicare Part D beneficiaries in DC pay an average of $8 to $22/month for generic ezetimibe depending on their plan's formulary tier and whether they have reached the catastrophic coverage phase.

How the Merck Zetia Savings Card Works in DC

Merck offers a Zetia Savings Card for commercially insured patients that can reduce out-of-pocket costs to as low as $0/month, subject to a monthly benefit cap and program eligibility rules. Patients must have commercial insurance that covers Zetia (brand) and must not be enrolled in any federal or state government health program, including DC Medicaid or Medicare [14].

DC residents who are commercially insured and prescribed brand Zetia can register at Merck's patient assistance site. The card covers the gap between what the plan pays and the patient's copay up to the stated monthly maximum. For 2026, the program maximum is subject to Merck's annual update; patients should verify the current cap at enrollment.

Uninsured DC residents who do not qualify for the savings card because they lack commercial insurance may apply for Merck's Patient Assistance Program, which can provide Zetia at no cost for qualifying low-income patients [14]. Income thresholds typically sit at or below 400% of the federal poverty level.

Generic ezetimibe is not eligible for the Merck Zetia Savings Card. Patients who want the deepest discount on generic ezetimibe should compare GoodRx, RxSaver, Cost Plus Drugs (Mark Cuban Cost Plus Drug Company), and their plan's mail-order pharmacy. Cost Plus Drugs listed ezetimibe 10 mg at approximately $6 for 30 tablets as of early 2025, which may undercut many retail pharmacy cash prices even in DC [15].

What's the Cheapest Way to Get Ezetimibe in DC?

The answer depends on your insurance status and clinical situation. For most uninsured DC residents, generic ezetimibe through a discount program or Cost Plus Drugs at roughly $6 to $15/month is the lowest cash-pay option [15]. For DC Medicaid enrollees, $0 copay after prior authorization approval is achievable. For patients in a HealthRX-affiliated telehealth program, compounded ezetimibe through a licensed 503A pharmacy can cost $0/month bundled into a subscription fee.

Using a 90-day supply instead of a 30-day fill can reduce per-unit cost by 10% to 20% at most DC pharmacies. Mail-order pharmacies contracted with FEHB plans or large employer plans routinely dispense a 90-day supply for the price of a 60-day copay.

Ezetimibe's safety profile supports long-term use. The most common adverse effects in IMPROVE-IT were upper respiratory infection (13.5% ezetimibe vs. 13.2% placebo) and myalgia (5.7% vs. 5.5%), rates that were not statistically different between groups [3]. Liver enzyme elevations above three times the upper limit of normal occurred in 1.8% of ezetimibe plus statin patients vs. 2.0% of statin-only patients, a finding that does not support routine liver function monitoring solely because of ezetimibe use [16].

The ACC/AHA guidelines note that "adding ezetimibe to a statin in patients with established ASCVD and LDL-C 70 mg/dL or higher is reasonable" and assign a Class IIa, Level of Evidence B-R recommendation to that combination [4]. That strength of evidence affects PA decisions and formulary positioning across DC payers.

Telehealth Prescribing of Zetia in DC

Telehealth prescribing of ezetimibe is fully legal in the District of Columbia. DC does not restrict prescribing of non-controlled cardiovascular medications via synchronous video or asynchronous telehealth platforms, provided the prescriber holds a valid DC medical license or is licensed in a state with which DC has a practice agreement [17].

The Ryan Haight Act applies only to controlled substances, so ezetimibe (a non-controlled drug) may be prescribed after a telehealth visit without requiring an in-person examination first [18]. DC-licensed telehealth providers on platforms such as HealthRX can order a lipid panel, review results, and issue an ezetimibe prescription entirely through a remote visit.

For patients already diagnosed with hyperlipidemia, refill prescriptions are routinely handled via patient messaging or asynchronous chart review in DC. DC's telehealth parity law (DC Code 31-3861 et seq.) requires commercial insurers to reimburse telehealth visits at rates equivalent to in-person visits for the same services, which keeps the cost of telehealth lipid management visits comparable to in-office visits [19].

Patients who receive a telehealth ezetimibe prescription can send it to any DC retail pharmacy, any mail-order pharmacy licensed to ship to DC, or a 503A compounding pharmacy if the prescriber writes for the compounded formulation. E-prescribing to DC pharmacies is standard; paper or phone prescriptions remain valid but slower.

Ezetimibe Dosing and Clinical Context for DC Patients

Ezetimibe 10 mg once daily is the only approved dose. It may be taken with or without food, at any time of day, and does not require dose adjustment for mild-to-moderate hepatic impairment; it is not recommended in patients with moderate-to-severe hepatic impairment [2].

The drug is most commonly prescribed in combination with a statin. The fixed-dose combination tablet Vytorin (ezetimibe 10 mg plus simvastatin) is available but less commonly prescribed since high-intensity statins (rosuvastatin, atorvastatin) are preferred over simvastatin for most high-risk patients per current guidelines [4]. Ezetimibe can also be combined with PCSK9 inhibitors (evolocumab, alirocumab) in patients with familial hypercholesterolemia or very high cardiovascular risk.

In the SHARP trial (N=9,270), ezetimibe plus simvastatin reduced major atherosclerotic events by 17% in chronic kidney disease patients (RR 0.83 to 95% CI 0.74 to 0.94, P<0.001) [20]. That trial is part of the evidence base supporting ezetimibe use in CKD patients, a population with elevated cardiovascular risk who may not tolerate high-intensity statin therapy.

The FOURIER trial (N=27,564) enrolled patients on maximally tolerated statin therapy who had baseline LDL-C of 70 mg/dL or higher; about 5% were also on ezetimibe at baseline, demonstrating that combination use is common in real-world high-risk populations [21]. When PCSK9 inhibitors are added, clinicians typically keep ezetimibe in the regimen as a lower-cost, well-tolerated LDL-lowering layer before escalating to injectable therapy.

Ezetimibe reduces LDL-C by an average of 18% to 20% as monotherapy and an additional 21% to 25% when added to a statin, based on a 2014 meta-analysis of 27 randomized trials (N=22,580) published in the European Heart Journal [22]. These reductions translate to meaningful long-term risk reduction: for every 1 mmol/L (38.7 mg/dL) reduction in LDL-C, major vascular events fall by approximately 22% according to the Cholesterol Treatment Trialists' Collaboration meta-analysis of 170,000 patients [23].

Monitoring and Follow-Up for DC Patients on Ezetimibe

No special monitoring is required for ezetimibe beyond standard lipid management follow-up. A fasting lipid panel 4 to 12 weeks after starting or changing the dose confirms the LDL-C response, consistent with ACC/AHA guidance [4]. Liver function tests are not routinely recommended unless the patient is also on a statin and has specific risk factors for hepatotoxicity [16].

Patients who experience myopathy symptoms (muscle pain, weakness, or dark urine) while on a statin-ezetimibe combination should have CK levels measured. Ezetimibe alone does not cause myopathy; any myopathy in combination therapy is attributed to the statin component [2].

Drug interactions are limited. Cyclosporine increases ezetimibe exposure significantly, so the combination requires caution and monitoring [2]. Cholestyramine and other bile acid sequestrants reduce ezetimibe absorption by approximately 55% and should be taken at least 2 hours before or 4 hours after ezetimibe [2]. Fibrates may increase biliary cholesterol secretion and the risk of cholelithiasis when combined with ezetimibe, though the risk is low in clinical practice [16].

For DC patients managing their lipid panel through a telehealth provider, lab orders can be placed at any LabCorp or Quest Diagnostics location in the District, or through at-home blood draw services that operate in DC. Results are typically available within 24 to 48 hours and can be reviewed with the prescriber at a follow-up telehealth visit.

Start with a lipid panel. If LDL-C remains above your personalized goal on maximally tolerated statin therapy, bring that result to your DC-licensed prescriber and ask whether ezetimibe 10 mg added to your current regimen is appropriate.